LY3537982

Other Medications

Experimental

Not available 1 Clinical Trials

Description

LY3537982 is an experimental oral medication currently being studied by Eli Lilly and Company. It is being investigated in clinical trials for patients with solid tumors that have a specific genetic mutation called KRAS G12C. In colorectal cancer, this drug is not yet approved for use. Clinical trials are ongoing to determine its safety, how well it is tolerated, and if it shows early signs of effectiveness in patients with KRAS G12C-mutated colorectal cancer. These trials are in the early phases (Phase 1), meaning the primary focus is on safety and finding the right dose.

Mechanism of Action

LY3537982 is designed to target the KRAS G12C protein, which is altered in some cancer cells. By targeting this specific protein, the drug aims to interfere with the signals that tell cancer cells to grow and divide. The specific way LY3537982 interacts with the KRAS G12C protein is being studied in clinical trials.

Side Effects

As LY3537982 is still in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. Information about side effects from these trials is not yet available to the public. Researchers will carefully monitor patients in the trials to identify and assess any side effects that occur.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04956640 Phase 1

Active, not recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

United States, Australia, Canada, France, Japan, South Korea

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.